Clinical Trial Update: A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors [Phase 2]

View source ↗

Summary

A phase 2 study evaluating tislelizumab in combination with radiotherapy as a second-line treatment for advanced biliary malignant tumors (cholangiocarcinoma) h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Cholangiocarcinoma | Phase 2 | Status: TERMINATED